Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER MCALLISTER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1033176896
CMS profile
1915
Location
FAIRFIELD, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$406,226.31

633 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $127,779.73 159
Lilly USA, LLC $96,027.87 72
H. Lundbeck A S $56,719.88 16
Axsome Therapeutics, Inc. $33,270.77 51
PFIZER INC. $23,511.97 46
Merz Pharmaceuticals, LLC $15,138.52 3
Dompe US, Inc. $14,348.31 9
ANI Pharmaceuticals, Inc. $13,785.34 11
Eli Lilly and Company $10,711.64 9
PFIZER INTERNATIONAL LLC $4,800.00 2
Lundbeck LLC $3,165.27 26
Eisai Inc. $2,085.29 8
UCB, Inc. $528.02 25
ARGENX US, INC. $469.27 21
Genentech USA, Inc. $429.73 20
Amneal Pharmaceuticals LLC $311.54 20
Novartis Pharmaceuticals Corporation $301.79 20
SCILEX PHARMACEUTICALS INC. $271.53 3
Amgen Inc. $261.90 11
CSL Behring $228.95 12
MDD US Operations, LLC $193.28 7
Boston Scientific Corporation $164.62 7
Abbott Laboratories $163.76 2
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $155.96 7
Mallinckrodt Hospital Products Inc. $151.45 3
Celgene Corporation $147.12 13
Takeda Pharmaceuticals U.S.A., Inc. $136.81 9
Ipsen Biopharmaceuticals, Inc $124.67 5
Grifols USA, LLC $117.98 4
JAZZ PHARMACEUTICALS INC. $112.98 4
Teva Pharmaceuticals USA, Inc. $93.66 4
EMD Serono, Inc. $68.77 3
Impel Pharmaceuticals LLC $60.55 3
HARMONY BIOSCIENCES LLC $54.45 2
VERTEX PHARMACEUTICALS INCORPORATED $48.87 2
Xeris Pharmaceuticals, Inc. $43.41 2
Supernus Pharmaceuticals, Inc. $35.63 1
Tonix Medicines, Inc. $31.64 2
Bausch Health US, LLC $30.00 1
Currax Pharmaceuticals LLC $29.10 2
Corium, LLC $23.77 1
Otsuka America Pharmaceutical, Inc. $22.98 1
GE HEALTHCARE $19.81 1
Neurocrine BioSciences, Inc. $18.61 1
Biogen, Inc. $14.78 1
Alnylam Pharmaceuticals Inc. $14.33 1

Page 3 of 13; records 101–150 of 633 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER MCALLISTER

NPI 1033176896 · CMS profile ID 1915

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FAIRFIELD, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 13; records 101–150 of 633 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033176896?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER MCALLISTER, NPI 1033176896, CMS profile ID 1915. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 13; records 101–150 of 633 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033176896?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PETER MCALLISTER, NPI 1033176896, CMS profile ID 1915. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 13; records 101–150 of 633 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033176896?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PETER MCALLISTER, NPI 1033176896, CMS profile ID 1915, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 13; records 101–150 of 633 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1033176896?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

633 matching records · $406,226.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 633 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 633.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $27.1910/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203043346 CMS
ABBVIE INC. $26.6610/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203043348 CMS
Lilly USA, LLC $25.6010/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186829764 CMS
ABBVIE INC. $1,472.5010/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1203043342 CMS
Genentech USA, Inc. $7.0010/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211566878 CMS
Genentech USA, Inc. $0.6310/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211566881 CMS
JAZZ PHARMACEUTICALS INC. $30.9110/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234321413 CMS
Lilly USA, LLC $1,450.0010/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186779083 CMS
Axsome Therapeutics, Inc. $12.3710/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235564854 CMS
VERTEX PHARMACEUTICALS INCORPORATED $27.1310/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213896485 CMS
ABBVIE INC. $25.6910/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203043340 CMS
Axsome Therapeutics, Inc. $12.3610/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235564839 CMS
Axsome Therapeutics, Inc. $8.5010/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235564842 CMS
ABBVIE INC. $3,250.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1203043338 CMS
HARMONY BIOSCIENCES LLC $18.0910/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222398514 CMS
Lilly USA, LLC $1,100.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186817862 CMS
Lilly USA, LLC $117.4310/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186817864 CMS
Lilly USA, LLC $907.2410/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186829760 CMS
Lilly USA, LLC $2,900.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186829778 CMS
Novartis Pharmaceuticals Corporation $25.5810/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597595 CMS
Axsome Therapeutics, Inc. $8.2510/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235564835 CMS
Impel Pharmaceuticals LLC $20.7910/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211450826 CMS
PFIZER INC. $14.4010/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230802229 CMS
Axsome Therapeutics, Inc. $3,263.0010/14/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235753341 CMS
Axsome Therapeutics, Inc. $125.0010/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235779830 CMS
Axsome Therapeutics, Inc. $31.5010/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1235810176 CMS
Celgene Corporation $17.9510/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184921274 CMS
Novartis Pharmaceuticals Corporation $4.6610/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597589 CMS
UCB, Inc. $0.2910/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224494461 CMS
UCB, Inc. $27.5910/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224494463 CMS
Boston Scientific Corporation $22.5410/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181153992 CMS
Mallinckrodt Hospital Products Inc. $26.0910/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211982334 CMS
Mallinckrodt Hospital Products Inc. $98.9910/10/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1211982336 CMS
Lilly USA, LLC $125.0010/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186798197 CMS
ABBVIE INC. $25.7110/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203043336 CMS
Amneal Pharmaceuticals LLC $22.6010/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220542335 CMS
JAZZ PHARMACEUTICALS INC. $30.4910/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234321843 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.9110/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223776417 CMS
ABBVIE INC. $20.4610/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203043334 CMS
CSL Behring $14.0010/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232351464 CMS
Novartis Pharmaceuticals Corporation $72.9810/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597581 CMS
PFIZER INC. $6.1010/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230388515 CMS
Currax Pharmaceuticals LLC $13.7510/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242706485 CMS
Novartis Pharmaceuticals Corporation $5.7910/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597587 CMS
ARGENX US, INC. $33.3310/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240435537 CMS
Axsome Therapeutics, Inc. $1,450.0010/02/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235754558 CMS
Dompe US, Inc. $4,550.0010/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1248880594 CMS
Dompe US, Inc. $7,105.4110/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248880596 CMS
Dompe US, Inc. $21.0210/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248880598 CMS
Dompe US, Inc. $795.8010/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248880600 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $246,954.27 634
PY2020 $266,275.18 625
PY2021 $327,692.93 696
PY2022 $421,856.02 774
PY2023 $330,387.34 684
PY2024 $301,896.66 606
PY2025 $406,226.31 633

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,128.13 9
PY2025 Principal investigator $2,010,823.12 443
PY2024 Recipient $9,120.00 1
PY2024 Principal investigator $2,244,731.55 346
PY2023 Recipient $36,295.26 9
PY2023 Principal investigator $1,621,983.46 236
PY2022 Recipient $962.00 3
PY2022 Principal investigator $2,128,116.24 90
PY2021 Recipient $3,258.80 6
PY2021 Principal investigator $2,093,701.91 321
PY2020 Recipient $2,622.45 2
PY2020 Principal investigator $1,143,007.78 136
PY2019 Recipient $19,905.66 7
PY2019 Principal investigator $1,443,942.42 235

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

452 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202532264
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533927
Principal investigator 1 ABBVIE INC. $1,082.56 12/31/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor No dispute reported 06/30/2026 1202533931
Principal investigator 1 PFIZER INC. $550.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703118
Principal investigator 1 PFIZER INC. $750.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703212
Principal investigator 1 PFIZER INC. $2,000.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703292
Principal investigator 1 PFIZER INC. $150.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703294
Principal investigator 1 PFIZER INC. $175.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703418
Principal investigator 1 PFIZER INC. $550.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703470
Principal investigator 1 PFIZER INC. $550.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703540
Principal investigator 1 PFIZER INC. $700.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703708
Principal investigator 1 PFIZER INC. $700.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703868
Principal investigator 1 PFIZER INC. $3,136.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704026
Principal investigator 1 PFIZER INC. $150.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704118
Principal investigator 1 PFIZER INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704184
Principal investigator 1 PFIZER INC. $1,500.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704268
Principal investigator 1 PFIZER INC. $2,500.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704340
Principal investigator 1 PFIZER INC. $750.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704344
Principal investigator 1 PFIZER INC. $175.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704508
Principal investigator 1 PFIZER INC. $3,136.00 12/31/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704522
Principal investigator 1 PFIZER INC. $40.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703120
Principal investigator 1 PFIZER INC. $218.40 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703194
Principal investigator 1 PFIZER INC. $287.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703196
Principal investigator 1 PFIZER INC. $164.50 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703198
Principal investigator 1 PFIZER INC. $245.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703210
Principal investigator 1 PFIZER INC. $341.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703284
Principal investigator 1 PFIZER INC. $259.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703286
Principal investigator 1 PFIZER INC. $318.50 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703288
Principal investigator 1 PFIZER INC. $318.50 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703290
Principal investigator 1 PFIZER INC. $245.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703366
Principal investigator 1 PFIZER INC. $164.50 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703368
Principal investigator 1 PFIZER INC. $294.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703370
Principal investigator 1 PFIZER INC. $104.30 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703416
Principal investigator 1 PFIZER INC. $287.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703472
Principal investigator 1 PFIZER INC. $266.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703474
Principal investigator 1 PFIZER INC. $313.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703476
Principal investigator 1 PFIZER INC. $104.30 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703538
Principal investigator 1 PFIZER INC. $350.70 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703546
Principal investigator 1 PFIZER INC. $313.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703612
Principal investigator 1 PFIZER INC. $259.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703614
Principal investigator 1 PFIZER INC. $245.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703616
Principal investigator 1 PFIZER INC. $338.10 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703618
Principal investigator 1 PFIZER INC. $347.20 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703620
Principal investigator 1 PFIZER INC. $287.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703706
Principal investigator 1 PFIZER INC. $341.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703710
Principal investigator 1 PFIZER INC. $338.10 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703714
Principal investigator 1 PFIZER INC. $40.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703716
Principal investigator 1 PFIZER INC. $217.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703786
Principal investigator 1 PFIZER INC. $245.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703788
Principal investigator 1 PFIZER INC. $313.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703870
Principal investigator 1 PFIZER INC. $350.70 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703950
Principal investigator 1 PFIZER INC. $313.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703952
Principal investigator 1 PFIZER INC. $341.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703954
Principal investigator 1 PFIZER INC. $287.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704016
Principal investigator 1 PFIZER INC. $245.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704120
Principal investigator 1 PFIZER INC. $341.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704182
Principal investigator 1 PFIZER INC. $266.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704192
Principal investigator 1 PFIZER INC. $499.30 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704194
Principal investigator 1 PFIZER INC. $245.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704342
Principal investigator 1 PFIZER INC. $313.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704352
Principal investigator 1 PFIZER INC. $287.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704356
Principal investigator 1 PFIZER INC. $294.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704400
Principal investigator 1 PFIZER INC. $313.60 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704402
Principal investigator 1 PFIZER INC. $217.00 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704512
Principal investigator 1 PFIZER INC. $499.30 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704582
Principal investigator 1 PFIZER INC. $218.40 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704584
Principal investigator 1 PFIZER INC. $347.20 12/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704764
Principal investigator 1 ABBVIE INC. $25,592.00 12/04/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528166
Principal investigator 1 Ipsen Innovation $4,060.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293339
Principal investigator 1 Ipsen Innovation $4,060.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293341
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293343
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293345
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293347
Principal investigator 1 Ipsen Innovation $4,060.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293349
Principal investigator 1 Ipsen Innovation $3,430.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293351
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293353
Principal investigator 1 H. Lundbeck A S $3,817.10 11/20/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251777509
Principal investigator 1 PFIZER INC. $11,853.71 11/20/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228817529
Principal investigator 1 Eli Lilly and Company $3,000.00 11/17/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187886246
Principal investigator 1 Merz Pharmaceuticals, LLC $24,211.89 11/17/2025 Non-covered Recipient Entity
Ki Health Partners LLC
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647402
Principal investigator 1 Merz Pharmaceuticals, LLC $4,658.00 11/17/2025 Non-covered Recipient Entity
Ki Health Partners LLC
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647404
Principal investigator 1 Ipsen Innovation $450.00 11/14/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289022
Principal investigator 1 ABBVIE INC. $25,536.00 11/05/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521361
Principal investigator 1 Ipsen Pharma SAS $4,000.00 10/31/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307147
Principal investigator 1 ABBVIE INC. $9,723.00 10/30/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202519825
Principal investigator 1 ABBVIE INC. $3,780.00 10/28/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202518811
Principal investigator 1 Ipsen Innovation $3,430.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293239
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293241
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293243
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293245
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293247
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293249
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293251
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293253
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293255
Principal investigator 1 Ipsen Innovation $3,430.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293257
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293259
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293261
Principal investigator 1 Ipsen Innovation $3,430.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293263
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293265
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293267
Principal investigator 1 Ipsen Innovation $4,970.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293269
Principal investigator 1 Ipsen Innovation $3,430.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293271
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293273
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293275
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293277
Principal investigator 1 Amgen Inc. $12,888.00 10/23/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246643370
Principal investigator 1 H. Lundbeck A S $4,741.45 10/23/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776016
Principal investigator 1 PFIZER INC. $550.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703116
Principal investigator 1 PFIZER INC. $2,000.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703414
Principal investigator 1 PFIZER INC. $1,000.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703536
Principal investigator 1 PFIZER INC. $2,500.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703542
Principal investigator 1 PFIZER INC. $550.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703544
Principal investigator 1 PFIZER INC. $1,500.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703784
Principal investigator 1 PFIZER INC. $3,507.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704116
Principal investigator 1 PFIZER INC. $700.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704180
Principal investigator 1 PFIZER INC. $550.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704354
Principal investigator 1 PFIZER INC. $700.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704510
Principal investigator 1 PFIZER INC. $750.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704520
Principal investigator 1 PFIZER INC. $750.00 10/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC DBA New England Institute for Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704580
Principal investigator 1 Genentech, Inc. $3,980.00 10/15/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211619899
Principal investigator 1 H. Lundbeck A S $631.00 10/15/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775646
Principal investigator 1 H. Lundbeck A S $2,625.00 10/15/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775650
Principal investigator 1 Ipsen Innovation $270.00 10/14/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289018
Principal investigator 1 Ipsen Innovation $150.00 10/14/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289020
Principal investigator 1 ABBVIE INC. $56,973.00 10/09/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202515897
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 10/01/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647386
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 10/01/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647388
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 10/01/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647390
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 10/01/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647392
Recipient PFIZER INC. $940.00 09/25/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802418
Recipient PFIZER INC. $330.00 09/25/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803053
Recipient PFIZER INC. $3,200.00 09/22/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802424
Principal investigator 1 H. Lundbeck A S $1,881.95 09/18/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251774844
Principal investigator 1 Ipsen Innovation $90.00 09/18/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289012
Principal investigator 1 Ipsen Innovation $150.00 09/18/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289014
Principal investigator 1 Ipsen Innovation $300.00 09/18/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289016
Principal investigator 1 H. Lundbeck A S $5,007.45 09/12/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251774627
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/11/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307135
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/11/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307137
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/11/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307139
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/11/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307141
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/11/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307143
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/11/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307145
Principal investigator 1 H. Lundbeck A S $3,354.00 09/10/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774514
Principal investigator 1 H. Lundbeck A S $2,534.00 09/10/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774517
Principal investigator 1 H. Lundbeck A S $631.00 09/10/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774521
Principal investigator 1 H. Lundbeck A S $2,625.00 09/10/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774525
Principal investigator 1 GENZYME CORPORATION $1,500.00 09/03/2025 Non-covered Recipient Entity
Ki Health Partners Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226092219
Principal investigator 1 Ipsen Innovation $3,430.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293163
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293165
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293167
Principal investigator 1 Ipsen Innovation $1,855.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293169
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293171
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293173
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293175
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293177
Principal investigator 1 Ipsen Innovation $4,060.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293179
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293181
Principal investigator 1 Ipsen Innovation $3,430.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293183
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293185
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293187
Principal investigator 1 Ipsen Innovation $4,060.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293191
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293193
Principal investigator 1 Ipsen Innovation $4,060.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293195
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293197
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293199
Principal investigator 1 Ipsen Innovation $3,430.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293201
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293203
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293205
Principal investigator 1 Ipsen Innovation $3,430.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293207
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293213
Principal investigator 1 PFIZER INC. $5,100.99 08/27/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228826803
Principal investigator 1 ABBVIE INC. $2,000.00 08/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202505787
Principal investigator 1 ABBVIE INC. $750.00 08/14/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202504627
Principal investigator 1 ABBVIE INC. $9,000.00 08/14/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202504629
Principal investigator 1 H. Lundbeck A S $13,769.30 08/14/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251773602
Principal investigator 1 Ipsen Innovation $10,000.00 08/14/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293189
Principal investigator 1 Ipsen Innovation $2,000.00 08/14/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293211
Principal investigator 1 Genentech, Inc. $12,000.00 08/13/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211619888
Principal investigator 1 Ipsen Innovation $1,500.00 08/13/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293161
Principal investigator 1 Ipsen Innovation $1,500.00 08/13/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293209
Principal investigator 1 Merz Pharmaceuticals, LLC $14,253.00 08/11/2025 Non-covered Recipient Entity
Ki Health Partners LLC
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647400
Principal investigator 1 Genentech, Inc. $16,000.00 08/08/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211619895
Principal investigator 1 Ipsen Pharma SAS $4,171.50 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307113
Principal investigator 1 Ipsen Pharma SAS $4,171.50 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307115
Principal investigator 1 Ipsen Pharma SAS $4,171.50 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307117
Principal investigator 1 ABBVIE INC. $15,995.00 08/06/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202502436
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288998
Principal investigator 1 Ipsen Innovation $150.00 07/31/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289010
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293081
Principal investigator 1 Ipsen Innovation $4,060.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293083
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293085
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293087
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293107
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293109
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293111
Principal investigator 1 Ipsen Innovation $1,050.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293113
Principal investigator 1 Ipsen Innovation $1,855.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293115
Principal investigator 1 Ipsen Innovation $1,855.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293117
Principal investigator 1 Ipsen Innovation $4,970.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293119
Principal investigator 1 Ipsen Innovation $4,900.00 07/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293121
Principal investigator 1 Ipsen Innovation $1,050.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293077
Principal investigator 1 Ipsen Innovation $1,050.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293079
Principal investigator 1 Ipsen Innovation $1,050.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293089
Principal investigator 1 Ipsen Innovation $4,970.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293123
Principal investigator 1 Ipsen Innovation $1,050.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293125
Principal investigator 1 ABBVIE INC. $1,500.00 07/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202499592
Principal investigator 1 H. Lundbeck A S $4,741.45 07/22/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251772764
Principal investigator 1 Ipsen Innovation $150.00 07/22/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289004
Principal investigator 1 Genentech, Inc. $3,620.00 07/21/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211619883
Principal investigator 1 ACADIA Pharmaceuticals Inc $12,500.00 07/18/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
ACP-204-006 No dispute reported 06/30/2026 1245935329
Principal investigator 1 H. Lundbeck A S $4,347.00 07/17/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251772380
Principal investigator 1 Ipsen Innovation $2,000.00 07/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293095
Principal investigator 1 Ipsen Innovation $10,000.00 07/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293097
Principal investigator 1 H. Lundbeck A S $11,500.00 07/16/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772360
Principal investigator 1 H. Lundbeck A S $3,000.00 07/16/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772364
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $4,471.60 07/16/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH
P255-501 No dispute reported 06/30/2026 1253059786
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $2,205.00 07/16/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH
P255-501 No dispute reported 06/30/2026 1253059792
Principal investigator 1 Ipsen Innovation $150.00 07/15/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289006
Principal investigator 1 Ipsen Innovation $270.00 07/15/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289008
Principal investigator 1 Ipsen Innovation $1,800.00 07/14/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293099
Principal investigator 1 Ipsen Innovation $90.00 07/08/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289000
Principal investigator 1 Ipsen Innovation $150.00 07/08/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289002
Principal investigator 1 ABBVIE INC. $1,227.50 07/02/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495271
Principal investigator 1 ABBVIE INC. $4,060.00 07/02/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202495443
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292917
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292919
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292921
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292923
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292925
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292927
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292929
Principal investigator 1 Ipsen Innovation $3,850.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292943
Principal investigator 1 Ipsen Innovation $3,850.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292945
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292947
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292949
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292951
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292953
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292955
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292957
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292959
Principal investigator 1 Ipsen Innovation $1,855.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292961
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292963
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292965
Principal investigator 1 Ipsen Innovation $3,850.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292967
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292969
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292971
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292973
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292981
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292983
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292985
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292987
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292989
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292991
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292993
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292995
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292997
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292999
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293001
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293003
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293005
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293007
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293009
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293011
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293013
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293015
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293017
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293019
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293021
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293023
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293025
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293027
Principal investigator 1 Ipsen Innovation $1,855.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293029
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293031
Principal investigator 1 Ipsen Innovation $3,850.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293033
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293035
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293037
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293041
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293043
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293045
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293047
Principal investigator 1 Ipsen Innovation $4,900.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293049
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293051
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293053
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293055
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293057
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293059
Principal investigator 1 Ipsen Innovation $4,060.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293061
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293063
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293065
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293067
Principal investigator 1 Ipsen Innovation $3,430.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293069
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293071
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293073
Principal investigator 1 Ipsen Innovation $4,900.00 06/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293075
Principal investigator 1 Genentech, Inc. $13,500.00 06/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211619876
Principal investigator 1 H. Lundbeck A S $5,007.45 06/24/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251771531
Principal investigator 1 H. Lundbeck A S $2,500.00 06/24/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251771536
Principal investigator 1 H. Lundbeck A S $1,500.00 06/24/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251771540
Principal investigator 1 H. Lundbeck A S $11,500.00 06/24/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251771544
Principal investigator 1 PFIZER INC. $10,618.89 06/13/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228829673
Principal investigator 1 Ipsen Innovation $300.00 06/12/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288996
Principal investigator 1 ABBVIE INC. $927.50 06/11/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202490881
Principal investigator 1 ABBVIE INC. $4,060.00 06/11/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490883
Principal investigator 1 H. Lundbeck A S $9,952.20 06/05/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770771
Principal investigator 1 Ipsen Innovation $450.00 05/23/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288992
Principal investigator 1 Ipsen Innovation $150.00 05/23/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288994
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 05/22/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS, LLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308688
Principal investigator 1 ABBVIE INC. $2,250.00 05/21/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202485611
Principal investigator 1 ABBVIE INC. $5,000.00 05/21/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202485613
Principal investigator 1 ABBVIE INC. $14,602.00 05/07/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482631
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $756.00 05/01/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH
P255-501 No dispute reported 06/30/2026 1253059796
Principal investigator 1 Ipsen Innovation $1,050.00 04/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292853
Principal investigator 1 H. Lundbeck A S $11,311.65 04/28/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769869
Principal investigator 1 Ipsen Innovation $3,850.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292739
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292741
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292743
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292745
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292747
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292749
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292751
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292753
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292755
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292757
Principal investigator 1 Ipsen Innovation $3,850.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292759
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292761
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292763
Principal investigator 1 Ipsen Innovation $175.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292765
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292767
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292769
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292771
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292773
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292775
Principal investigator 1 Ipsen Innovation $175.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292777
Principal investigator 1 Ipsen Innovation $1,855.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292779
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292781
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292783
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292785
Principal investigator 1 Ipsen Innovation $3,850.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292787
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292789
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292791
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292793
Principal investigator 1 Ipsen Innovation $1,855.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292795
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292797
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292799
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292801
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292803
Principal investigator 1 Ipsen Innovation $3,850.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292805
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292807
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292809
Principal investigator 1 Ipsen Innovation $4,900.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292811
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292813
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292815
Principal investigator 1 Ipsen Innovation $4,900.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292817
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292819
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292821
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292823
Principal investigator 1 Ipsen Innovation $175.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292825
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292827
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292829
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292831
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292833
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292835
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292837
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292839
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292841
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292843
Principal investigator 1 Ipsen Innovation $4,900.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292845
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292847
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292849
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292851
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292855
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292857
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292859
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292861
Principal investigator 1 Ipsen Innovation $175.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292863
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292865
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292867
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292869
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292871
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292873
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292875
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292877
Principal investigator 1 Ipsen Innovation $175.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292879
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292881
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292883
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292885
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292887
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292889
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292891
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292893
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292895
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292897
Principal investigator 1 Ipsen Innovation $4,970.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292899
Principal investigator 1 Ipsen Innovation $175.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292901
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292903
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292905
Principal investigator 1 Ipsen Innovation $4,900.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292907
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292909
Principal investigator 1 Ipsen Innovation $4,060.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292911
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292913
Principal investigator 1 Ipsen Innovation $1,050.00 04/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292915
Principal investigator 1 PFIZER INC. $919.80 04/24/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228832370
Principal investigator 1 Ipsen Innovation $150.00 04/21/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288982
Principal investigator 1 Ipsen Innovation $90.00 04/21/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288984
Principal investigator 1 Ipsen Innovation $150.00 04/21/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288986
Principal investigator 1 Ipsen Innovation $450.00 04/18/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288988
Principal investigator 1 Ipsen Innovation $600.00 04/18/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288990
Principal investigator 1 Merz Pharmaceuticals, LLC $8,402.00 04/10/2025 Non-covered Recipient Entity
Ki Health Partners LLC
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647398
Principal investigator 1 Ipsen Innovation $600.00 04/09/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288976
Principal investigator 1 Ipsen Innovation $360.00 04/09/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288978
Principal investigator 1 Ipsen Innovation $300.00 04/09/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288980
Principal investigator 1 H. Lundbeck A S $5,007.45 04/08/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769478
Recipient ABBVIE INC. $230.64 04/02/2025 Covered Recipient Physician Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202399858
Recipient ABBVIE INC. $6.16 04/02/2025 Covered Recipient Physician Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202399861
Recipient ABBVIE INC. $141.67 04/02/2025 Covered Recipient Physician Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202399867
Recipient ABBVIE INC. $32.44 04/02/2025 Covered Recipient Physician Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202399872
Recipient ABBVIE INC. $216.34 04/02/2025 Covered Recipient Physician Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202399876
Recipient ABBVIE INC. $30.88 04/02/2025 Covered Recipient Physician Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202399881
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $750.00 03/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH
P255-501 No dispute reported 06/30/2026 1253059750
Principal investigator 1 Eli Lilly and Company $514.50 03/25/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187885622
Principal investigator 1 Eli Lilly and Company $6.00 03/23/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187883972
Principal investigator 1 PFIZER INC. $5,671.59 03/13/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831232
Principal investigator 1 H. Lundbeck A S $11,645.10 03/11/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768615
Principal investigator 1 ABBVIE INC. $13,295.00 03/06/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202457706
Principal investigator 1 H. Lundbeck A S $12,606.30 03/04/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251768048
Principal investigator 1 Eli Lilly and Company $305.20 02/25/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885784
Principal investigator 1 Genentech, Inc. $3,620.00 02/18/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211619879
Principal investigator 1 ABBVIE INC. $6,030.00 02/05/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202445621
Principal investigator 1 H. Lundbeck A S $4,347.00 02/05/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766999
Principal investigator 1 Eli Lilly and Company $135,321.00 02/04/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885786
Principal investigator 1 Ipsen Innovation $1,050.00 01/31/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292731
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,365.94 01/31/2025 Non-covered Recipient Entity
NEW ENGLAND INSTITUTE FOR NEUROLOGY AND HEADACHE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307559
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,359.15 01/27/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995401
Principal investigator 1 Eli Lilly and Company $8,275.14 01/27/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187883970
Principal investigator 1 Ipsen Innovation $3,850.00 01/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292733
Principal investigator 1 Ipsen Innovation $175.00 01/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292735
Principal investigator 1 Ipsen Innovation $1,855.00 01/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292737
Principal investigator 1 Ipsen Innovation $1,050.00 01/23/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288972
Principal investigator 1 Ipsen Innovation $270.00 01/23/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288974
Principal investigator 1 PFIZER INC. $3,843.90 01/23/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831283
Principal investigator 1 Eli Lilly and Company $25,201.00 01/21/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885620
Principal investigator 1 Ipsen Innovation $720.00 01/20/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288968
Principal investigator 1 Ipsen Innovation $150.00 01/20/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288970
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $159,125.00 01/16/2025 Non-covered Recipient Entity
New England Institute For Neurology And Headache
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995399
Principal investigator 1 PFIZER INC. $4,984.89 01/16/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831276
Principal investigator 1 PFIZER INC. $17,549.57 01/16/2025 Non-covered Recipient Entity
Ki Health Partners LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831334
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $281,634.25 01/15/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
Efficacy, Safety and Tolerability of Lumateperone in Inadequately Controlled Migraine Patients with and without Comorbid Bipolar Disorder or Depression No dispute reported 06/30/2026 1242328703
Principal investigator 1 Eli Lilly and Company $143,954.00 01/08/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187883968
Principal investigator 1 H. Lundbeck A S $5,639.20 01/07/2025 Non-covered Recipient Entity
KI CLINICAL RESEARCH
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766252
Principal investigator 1 Merz Pharmaceuticals, LLC $4,227.00 01/06/2025 Non-covered Recipient Entity
Ki Health Partners LLC
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647396